Gilead and Arcus Biosciences terminated additional TIGIT-focused studies after Phase 3 domvanalimab results failed to meet efficacy goals in metastatic non-small-cell lung cancer. In securities filings, Arcus said an independent data panel found the trial comparison against Merck’s Keytruda plus chemotherapy futile, prompting rollback steps including the discontinuation of the Phase 2 EDGE-Lung study. Gilead also declined an option continuation payment, ending access to multiple early-stage TIGIT assets by mid-July, though existing time-limited options were retained for specific programs. The decision further narrows the field for anti-TIGIT combinations, following other TIGIT program setbacks, and may drive companies to refocus on different immune checkpoint strategies or biomarkers.